Gain Therapeutics, Inc.

GANX

Gain Therapeutics, Inc.

GANX

Insider Sentiment (TTM):

Last Purchase:2024-08-09Last Sale:2023-12-21Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:7,302,394Shares Outstanding:42,230,248Institutional Ownership Pct.:17.29%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	13	17	21	9	7	9	10	12	17	11	12	4
Marketable Securities Current	-	-	-	-	-	-	-	-	-	2	5	8
Deferred Income Taxes And Other Tax Receivable Cur…	0	0	0	0	0	0	0	0	0	0	0	0
Prepaid Expense And Other Assets Current	2	1	1	1	2	2	1	1	1	1	1	1
Assets Current	15	18	22	11	9	11	12	14	19	14	18	13
Assets Noncurrent
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Capitalized Computer Software Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0	0	0
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets Noncurrent	0	1	1	0	1	0	1	1	1	1	1	1
Assets	15	19	23	11	10	12	12	14	19	15	19	14
Liabilities And Stockhold…
Liabilities
Liabilities Current
Accounts Payable Current	1	2	1	2	3	2	1	1	2	1	1	1
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Other Liabilities Current	2	2	2	2	2	2	2	2	3	2	2	3
Deferred Income Current	-	-	-	0	0	0	0	1	1	1	1	1
Long Term Debt Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	3	4	3	4	5	5	4	5	7	5	5	6
Liabilities Noncurrent
Defined Benefit Pension Plan Liabilities Noncurren…	0	0	0	1	1	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Income Noncurrent	-	-	-	-	-	-	0	0	0	0	0	0
Long Term Debt Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Liabilities	4	5	4	5	6	6	5	5	7	6	6	7
Stockholders Equity
Preferred Stock Value	-	-	-	-	-	-	-	0	0	0	-	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	122	120	119	102	95	92	89	86	85	73	73	63
Accumulated Other Comprehensive Income Loss Net Of…	1	1	1	1	1	-0	-0	0	0	0	0	0
Retained Earnings Accumulated Deficit	-112	-101	-81	-81	-81	-81	-61	-61	-61	-61	-39	-
Stockholders Equity	11	14	19	6	4	6	7	9	12	9	13	7
Liabilities And Stockholders Equity	15	19	23	11	10	12	12	14	19	15	19	14
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	100	100	100	100	50	50	100	50	50	50	50	50
Common Stock Shares Issued	43	42	42	36	31	29	27	26	25	18	16	13
Shares Outstanding	43	42	42	36	31	29	27	26	25	18	16	13

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.59%	4.95%	-3.30%	-	-	-	-	-	-	-	-	-
2025	3.23%	-9.14%	-22.58%	15.03%	25.49%	28.10%	30.51%	7.80%	-38.98%	12.70%	-7.41%	-11.11%
2024	-5.98%	-48.72%	-55.13%	12.72%	105.79%	174.04%	2.58%	39.26%	22.06%	-13.04%	-2.90%	-16.43%
2023	-	-	-	-	-	-	-2.16%	34.89%	41.73%	-16.32%	-30.79%	-67.37%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.36	4.69	6.63	2.52	1.79	2.22	2.97	2.99	2.84	2.77	3.59	2.30
Quick Ratio	3.87	4.31	6.27	2.18	1.35	1.85	2.72	2.70	2.64	2.58	3.44	2.14
Working Capital	11.54M	14.34M	18.88M	6.35M	4.11M	6.12M	7.69M	9.15M	12.02M	8.86M	12.83M	7.48M
Leverage & Debt
Debt to Equity	0.37	0.34	0.23	0.86	1.66	1.01	0.65	0.61	0.63	0.69	0.48	0.92
Interest Coverage TTM	-61.13	-66.31	-76.56	-82.55	-71.80	-72.08	-56.99	-52.07	-53.03	-46.78	-45.03	-40.61
Debt Ratio	0.27	0.25	0.19	0.46	0.62	0.50	0.39	0.38	0.39	0.41	0.32	0.48
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01
Per Share Metrics
Diluted EPS TTM	-0.47	-0.50	-0.61	-0.55	-0.61	-0.73	-0.89	-0.81	-1.12	-1.18	-1.71	-1.75
Free Cash Flow Per Share TTM	-0.42	-0.46	-0.56	-0.39	-0.48	-0.67	-0.83	-0.80	-0.99	-1.02	-1.45	-1.35
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-39,602.68%	-19,392.03%	-13,442.75%	-14,175.25%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-39,143.72%	-19,159.47%	-13,451.44%	-14,055.63%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-77.29%	-60.99%	-39.31%	-62.17%
Net Income Growth (1Y)	8.14%	1.49%	-1.23%	-9.24%	-13.92%	-1.03%	-8.34%	-3.83%	-2.08%	8.68%	26.59%	37.69%
EPS Growth (1Y)	-23.48%	-31.06%	-31.45%	-31.20%	-45.48%	-37.97%	-47.88%	-53.96%	-36.88%	-27.85%	15.61%	28.82%
Valuation Metrics
P/E TTM	-4.33	-3.86	-5.27	-3.19	-2.94	-2.62	-2.42	-2.21	-1.14	-3.21	-1.91	-1.88
P/B TTM	7.71	5.85	5.72	10.48	14.78	9.48	6.73	5.30	2.09	7.84	3.38	5.68
P/S TTM	-	-	-	-	-	-	-	-	445.74	614.18	256.63	263.55
Market Cap	87.05M	81.93M	106.16M	61.95M	54.61M	54.79M	49.42M	47.23M	24.60M	67.78M	42.48M	41.66M
Enterprise Value	74.27M	65.72M	110.36M	53.53M	48.34M	46.11M	39.44M	35.64M	8.11M	57.62M	31.22M	37.90M
Calculated Values
Free Cash Flow TTM	-18.05M	-19.37M	-18.47M	-13.48M	-14.63M	-19.13M	-18.90M	-21.10M	-18.99M	-18.25M	-18.89M	-17.15M
Net Debt	-12.78M	-16.20M	4.20M	-8.42M	-6.28M	-8.68M	-9.98M	-11.59M	-16.48M	-10.17M	-11.26M	-3.76M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-08-09Purchase

Owner: Mack, Gene

Title: CFO and Interim CEO

Shares: 14,400

Price/Share: $1.01

Value: $14,544.00

Shares Owned: 14,400

Relationship: Officer

Ownership: Direct

2024-08-09Purchase

Owner: Islam, Khalid

Title: Executive Chairman

Shares: 50,000

Price/Share: $1.00

Value: $50,000.00

Shares Owned: 50,000

Relationship: Director,Officer

Ownership: Direct

2024-07-01Purchase

Owner: Richman, Eric I

Title: -

Shares: 17,000

Price/Share: $1.22

Value: $20,740.00

Shares Owned: 289,629

Relationship: Director

Ownership: Direct

2024-03-28Purchase

Owner: Riley, Jeffrey Scott

Title: -

Shares: 30,000

Price/Share: $3.86

Value: $115,800.00

Shares Owned: 30,000

Relationship: Director

Ownership: Direct

2023-12-21Sale

Owner: Alder, Matthias

Title: Chief Executive Officer

Shares: 206

Price/Share: $2.46

Value: $506.76

Shares Owned: 5,286

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-08-09	Mack, Gene	Officer	CFO and Interim CEO	Direct	Purchase	14,400	1.01	$14,544.00	14,400	4
2024-08-09	Islam, Khalid	Director,Officer	Executive Chairman	Direct	Purchase	50,000	1.00	$50,000.00	50,000	4
2024-07-01	Richman, Eric I	Director	-	Direct	Purchase	17,000	1.22	$20,740.00	289,629	4
2024-03-28	Riley, Jeffrey Scott	Director	-	Direct	Purchase	30,000	3.86	$115,800.00	30,000	4
2023-12-21	Alder, Matthias	Director,Officer	Chief Executive Officer	Direct	Sale	206	2.46	$506.76	5,286	4
2023-12-07	Alder, Matthias	Director,Officer	Chief Executive Officer	Direct	Sale	1,820	2.50	$4,550.00	4,855	4
2022-05-25	Richman, Eric I	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Purchase	2,482	2.58	$6,403.56	217,729	4
2022-05-20	Richman, Eric I	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Purchase	9,256	2.83	$26,194.48	215,247	4
2022-05-19	Calabrese, Salvatore	Officer	CHIEF FINANCIAL OFFICER	Direct	Purchase	3,000	2.70	$8,100.00	3,000	4/A
2021-08-16	Richman, Eric I	Director,Officer	Chief Executive Officer	Direct	Purchase	4,922	7.87	$38,736.14	216,820	4/A
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

17.29%

Inst. Shares: 7,302,394

Shares Outstanding: 42,230,248

2025-12-31

22.48%

Inst. Shares: 7,412,171

Shares Outstanding: 32,968,336

2025-09-30

11.29%

Inst. Shares: 3,949,684

Shares Outstanding: 34,998,060

2025-06-30

11.75%

Inst. Shares: 3,566,367

Shares Outstanding: 30,341,523

2025-03-31

8.09%

Inst. Shares: 2,320,109

Shares Outstanding: 28,685,417

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	7,302,394	42,230,248	17.29%
2025-12-31	7,412,171	32,968,336	22.48%
2025-09-30	3,949,684	34,998,060	11.29%
2025-06-30	3,566,367	30,341,523	11.75%
2025-03-31	2,320,109	28,685,417	8.09%
2024-12-31	1,929,181	22,881,415	8.43%
2024-09-30	1,670,376	26,531,747	6.30%
2024-06-30	3,000,343	19,215,582	15.61%
2024-03-31	1,801,997	17,978,951	10.02%
2023-12-31	1,498,050	13,011,361	11.51%
2023-09-30	1,460,029	12,701,401	11.50%
2023-06-30	1,130,214	12,387,089	9.12%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Gain Therapeutics, Inc. (GANX) — SEC Financial Statements & Analysis

Gain Therapeutics, Inc. (GANX) is a pharmaceutical preparations company, incorporated in DE. Gain Therapeutics, Inc. trades on Nasdaq as: GANX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Gain Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.37x, a Price-to-Sales (P/S) ratio of 445.74x (TTM), a Price-to-Book (P/B) ratio of 7.71x (TTM), at a market cap of $87.05M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.37x
P/S TTM: 445.74x
P/B TTM: 7.71x
Market Cap: $87.05M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Gain Therapeutics, Inc. in?

Gain Therapeutics, Inc. (GANX) operates in the Pharmaceutical Preparations industry.

What is GANX's market cap?

Gain Therapeutics, Inc. (GANX) has a market capitalization of $87.05M as of 2026-06-30.

What exchange does GANX trade on?

Gain Therapeutics, Inc. (GANX) trades on the Nasdaq.

Where is Gain Therapeutics, Inc. incorporated?

Gain Therapeutics, Inc. is incorporated in DE.